(Received for publication, September 13, 1996, and in revised form, December 5, 1996)
From the First Department of Medicine, Toyama Medical & Pharmaceutical University, 2630 Sugitani, Toyama 930-01, Japan and the § Banting and Best Department of Medical Research, University of Toronto, Toronto, Ontario M5G 1L6, Canada
Shc is phosphorylated on Tyr-317,
which serves as a docking site for Grb2. To investigate the specific
role of Shc phosphorylation and Shc·Grb2 coupling on insulin
signaling, we generated expression vectors for wild-type (WT-Shc) and a
mutant Shc with a Tyr-317 Phe substitution (317Y/F-Shc) and stably
transfected them into Rat1 fibroblasts expressing insulin receptors
(HIRc). From different clonal cell lines, cells expressing 10 times
greater amounts of WT-Shc or 317Y/F-Shc compared with endogenous Shc
were chosen for analysis of insulin signaling. Insulin-induced Shc
phosphorylation and subsequent association with Grb2 was enhanced in
WT-Shc cells. Because of competition between Shc and IRS-1 for
interaction with the insulin receptor, insulin-stimulated tyrosine
phosphorylation of IRS-1 was decreased in WT-Shc cells compared with
that in HIRc cells. Likewise, reduction of endogenous Shc expression by
antisense Shc mRNA resulted in increased insulin stimulation of
IRS-1 phosphorylation. Although 317Y/F-Shc was also able to interact
with insulin receptor, decreased amounts of Shc phosphorylation and Shc
association with Grb2 were observed in 317Y/F-Shc cells, indicating
that 317Y/F-Shc functions as a dominant-negative mutant. The kinetics
of mitogen-activated protein (MAP) kinase activation closely paralleled
the kinetics of Shc phosphorylation. Thus, insulin stimulation of MAP
kinase activation occurred more rapidly and was prolonged in WT-Shc
cells, while the activation was delayed and transient in 317Y/F-Shc
cells compared with that in HIRc cells. Importantly, WT-Shc cells
displayed enhanced sensitivity to insulin stimulation of thymidine and
bromodeoxyuridine incorporation, whereas the sensitivity was decreased
in 317Y/F-Shc cells. These results indicate that Shc Tyr-317
phosphorylation plays an important role, via coupling with Grb2 and
competition with IRS-1, in signal transduction to MAP kinase by
insulin, ultimately leading to mitogenesis in Rat1 fibroblasts.
The activated insulin receptor phosphorylates various cellular substrates on tyrosine residues (1). One of the substrates of the insulin receptor is insulin receptor substrate 1 (IRS-1)1 (2). Tyrosine-phosphorylated IRS-1 functions as a multisite docking protein to interact with the Src homology 2 (SH2) domains of various signal-transducing molecules, including Grb2, the p85 regulatory subunit of PI3-kinase, protein-tyrosine phosphatase SH-PTP2 (also called Syp, PTP1D, and PTP2C), Nck, and Fyn, to propagate the insulin signal downstream (1, 3). Recently, insulin receptor substrate 2 (IRS-2) was cloned as an alternative substrate of the insulin receptor and appears to play some physiological roles in insulin signal transduction with coupling mechanisms similar to IRS-1 (4). In addition to IRS-1 and IRS-2, another substrate of the insulin receptor termed Shc has been identified (5). Shc has been implicated in mitogenic signaling by a variety of receptors for growth factors such as insulin, epidermal growth factor, platelet-derived growth factor, and nerve growth factor (5-10). Previous studies examined the role of Shc in insulin-induced mitogenic signaling, primarily using the transient expression of wild-type Shc or the microinjection of anti-Shc antibody, and demonstrated the importance of Shc in insulin's mitogenic signal transduction (11-13).
Shc is composed of three distinct domains: an amino-terminal region called the phosphotyrosine binding domain, a collagen homology domain, and a carboxyl-terminal SH2 domain (5, 14-17). Shc has been shown to be involved in the activation of p21ras, which plays a pivotal role in signal transduction initiated by tyrosine kinases of insulin and other growth factor receptors (13, 18, 19). Shc is tyrosine-phosphorylated upon insulin stimulation and subsequently associates with Grb2, which forms a complex with Sos, a p21ras guanine nucleotide exchange factor (5, 18, 20). Shc·Grb2 binding is mediated by the SH2 domain of Grb2 binding to phosphorylated Tyr-317 in the collagen homology domain of Shc suggesting that Tyr-317 plays a key role in insulin signaling (5, 21). Shc has been reported to associate with at least three other downstream signaling molecules in addition to Grb2, although the function of these Shc-binding proteins remains to be clarified. First, PEST tyrosine phosphatase has been shown to associate with Shc (22). Two serine residues at positions 5 and 29 in the amino terminus of Shc are suggested to be a sites regulating binding to the PEST protein-tyrosine phosphatase. Second, adaptins bind to Shc and are thought to be involved in receptor endocytosis (23). Amino acids 346-355 in the collagen homology domain of Shc are required for adaptin binding. Third, a tyrosine-phosphorylated 145-kDa protein has been shown to bind to Shc (14). Recently, this has been cloned and named SHIP, for SH2-containing inositol phosphatase (24). The amino terminus of Shc (amino acids 46-232) appeared to be responsible for SHIP binding. The Drosophila Shc homologue lacks the tyrosine residue corresponding to the mammalian Grb2 binding site and does not interact with the Drosophila Grb2 homologue (Drk) (25). This finding suggests that, at least in Drosophila, Shc may play a role other than p21ras activation via Shc·Grb2 association. Therefore, although the functional role of Shc as the signal-transducing molecule has been elucidated, the importance of the phosphorylation of Shc Tyr-317 for insulin's biological action has not been clearly demonstrated.
In the present study, to directly clarify the specific role of Shc
Tyr-317 phosphorylation and Grb2 association via Shc Tyr-317 residue on
insulin signaling, we generated an Shc cDNA with a Tyr-317 Phe
point mutation (317Y/F-Shc). The mutant 317Y/F-Shc plasmids were stably
transfected into Rat1 fibroblasts overexpressing insulin receptors, and
intracellular insulin signaling leading to the mitogenic effect of
insulin was examined in these cell lines.
Porcine insulin was a kind gift from Shimizu Pharmaceutical Co. (Shizuoka, Japan). [3H]Thymidine (83 Ci/mmol) was purchased from DuPont NEN. A polyclonal anti-Shc antibody, a monoclonal anti-Grb2 antibody, and a monoclonal anti-phosphotyrosine antibody (pY20) were from Transduction Laboratories (Lexington, KY). Bromodeoxyuridine (BrdUrd), a monoclonal anti-BrdUrd antibody, and enhanced chemiluminescence reagents were from Amersham Corp. Rhodamine-conjugated anti-mouse IgG antibody was from Jackson Laboratories (West Grove, NY). A polyclonal anti-IRS-1 antibody was kindly provided by Dr. Hiroshi Maegawa (Shiga University of Medical Science, Japan). Electrophoresis reagents were from Bio-Rad. All other reagents were analytical grade and purchased from Sigma or Wako Pure Chemical Industries, Ltd. (Osaka, Japan).
Plasmid ConstructionThe human Shc cDNA was isolated
from human fibroblasts. Two overlapping Shc clones were synthesized by
reverse transcription-polymerase chain reaction from mRNA of human
fibroblast cells. Primers used in the polymerase chain reaction were:
5-GGCCCTGGACATGAACAAGC-3
(sense strand), 5
-CATAGGCGACATACTCGGCT-3
(antisense strand), 5
-ATGCAATCTATCTCATTTGC-3
(sense strand), and
5
-TGACTCAAACCCTCTCACTC-3
(antisense strand). The nucleotide sequences
of these clones were verified with various internal primers and were
totally consistent with the published sequence (5), and then these
clones were ligated at the BamHI site. The resulting
fragment containing the entire coding region was filled with Klenow
fragment and inserted into the EcoRV site of the mammalian
expression vector Rldn to yield RldnWT-Shc; Rldn was kindly provided by
Dr. Allan R. Shatzman (SmithKline Beecham). To generate a mutant Shc
cDNA encoding the Tyr-317
Phe point mutation, polymerase chain
reaction was performed with a mutagenic oligonucleotide
(5
-CTGGACGTTGACGGAGGGAT-3
, antisense strand) including
the native HincII site and primers listed above. The mutant
317Y/F-Shc cDNA was also cloned into the EcoRV site of
Rldn (RldnMT-Shc).
Rat1 fibroblasts expressing 1 × 106 human insulin receptors per cell (HIRc) were kindly supplied by Dr. J. M. Olefsky (University of California, San Diego) and were maintained in Dulbecco's modified Eagle's medium/F-12 medium supplemented with 10% fetal calf serum (26). To establish antisense Shc-expressing cells, WT-Shc cDNA was cloned in the negative orientation into Rldn (RldnAS-Shc). HIRc cells (5 × 105 cells per dish) were transfected with 20 µg of RldnWT-Shc, Rldn317Y/F-Shc, or RldnAS-Shc and 2 µg of pcDEB carrying a hygromycin-resistant gene using calcium phosphate methods for 72 h. Hygromycin B (400 µg/ml) was then added to the medium to select for resistant cells. Cells expressing high levels of the wild-type Shc, the 317Y/F mutant Shc, or the antisense Shc were isolated by limiting dilution and then chosen by immunoblotting with anti-Shc antibody.
Immunoprecipitation and Western BlottingCells were serum-starved for 24 h and then incubated with 17 nM insulin for the indicated times. The cells were lysed in a solubilizing buffer containing 30 mM Tris, 150 mM NaCl, 10 mM EDTA, 0.5% sodium deoxycholate, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM Na3VO4, 160 mM NaF, pH 7.4, for 15 min at 4 °C. Lysates obtained from the same number of cells for each cell line were centrifuged to remove insoluble material, and the supernatants were used for immunoprecipitation with the specified antibodies for 3 h at 4 °C. The immunoprecipitates, the remaining supernatants, or whole cell lysates were separated by 7.5% SDS-PAGE and transferred onto polyvinylidene difluoride membranes by electroblotting. The membranes were blocked with 2.5% bovine serum albumin and probed with the specified antibodies. Enhanced chemiluminescence detection was performed according to the manufacturer's instructions (Amersham Corp.).
Thymidine IncorporationCells were grown to confluence in 24 multiwell culture plates and serum-starved for 24 h. After stimulation of the cells with various concentrations of insulin for 20 h, 1 µCi of [3H]thymidine was added for 4 h. The cells were washed twice with ice-cold phosphate-buffered saline, twice with ice-cold 10% trichloroacetic acid, and once with 95% ethanol. The cells were dissolved in 1 N NaOH, neutralized with 1 N HCl, and counted in a liquid scintillation counter (27).
BrdUrd IncorporationCells were grown on glass coverslips and rendered quiescent by starvation for 24 h. Serum-starved cells were incubated with BrdUrd plus various concentrations of insulin for 16 h at 37 °C. The cells were fixed with acid alcohol (90% ethanol, 5% acetic acid) for 20 min at 22 °C and then incubated with mouse monoclonal anti-BrdUrd antibody for 1 h at 22 °C. The cells were then stained by incubation with rhodamine-labeled donkey anti-mouse IgG antibody for 1 h at 22 °C. After the coverslips were mounted, the cells were analyzed with a Microphot-FXA fluorescence microscope (Nikon, Tokyo, Japan) (12).
We generated mutant Shc cDNA encoding a Tyr-317 Phe
mutation by primer-directed in vitro mutagenesis (Fig.
1A). Both the wild-type Shc and the mutant
317Y/F-Shc expression plasmids were transfected into HIRc cells, and
clones resistant to hygromycin B were selected. From hygromycin
B-resistant clones five independent cell lines overexpressing the
wild-type Shc (WT-Shc) or the mutant Shc (317Y/F-Shc) were obtained by
immunoblotting the cell lysates with anti-Shc antibody. Each cell line
chosen for further study expressed a 10 times greater amount of
wild-type Shc or 317Y/F-Shc compared with endogenous Shc in HIRc cells
(Fig. 1B).
Insulin-induced Tyrosine Phosphorylation of Shc in the Transfected Cell Lines
Shc phosphorylation in response to insulin was
examined in the transfected cells. The transfected cells were incubated
with 17 nM insulin for the indicated times, and the cell
lysates were subjected to immunoprecipitation with anti-Shc antibody.
The immunoprecipitates were analyzed by immunoblotting with
anti-phosphotyrosine antibody as shown in Fig.
2A. Overexpression of wild-type or 317Y/F
mutant Shc had no effect on tyrosine phosphorylation of Shc in the
basal state. Insulin stimulated tyrosine phosphorylation of 52-kDa Shc in a time-dependent manner in HIRc cells. In cells
overexpressing wild-type Shc, insulin-stimulated Shc tyrosine
phosphorylation was faster, and a greater amount of Shc was
phosphorylated compared with HIRc cells. In contrast,
insulin-stimulated tyrosine phosphorylation of Shc was decreased in
317Y/F-Shc cells compared with that in HIRc cells. These results are
summarized in Fig. 2B. Following 10 min of insulin
stimulation, Shc phosphorylation was increased to 137 ± 23% in
WT-Shc cells and decreased to 27 ± 14% in 317Y/F-Shc cells
compared with that in HIRc cells.
Effects of Shc Overexpression on Tyrosine Phosphorylation of IRS-1
Both Shc and IRS-1 bind to the juxtamembrane domain
centered on Tyr-960 of the insulin receptor -subunit (15, 28).
Therefore, it can be speculated that Shc and IRS-1 serve as competitive
substrates of the insulin receptor. To test this, we examined the
effect of Shc overexpression on insulin-induced IRS-1 phosphorylation in the transfected cell lines. The cells were incubated with 17 nM insulin for the indicated times, and the cell lysates
were analyzed by immunoblotting with anti-phosphotyrosine antibody as
shown in Fig. 3A. Overexpression of wild-type
or 317Y/F mutant Shc had no significant effect on basal tyrosine
phosphorylation of either IRS-1 or the insulin receptor
-subunit,
which were barely detected in each cell line. In addition,
overexpression of Shc did not affect the insulin-stimulated tyrosine
phosphorylation of insulin receptor
-subunit. Insulin stimulated
tyrosine phosphorylation of IRS-1 in HIRc cells, peaking at 1 min and
declining thereafter. Importantly, insulin-stimulated tyrosine
phosphorylation of IRS-1 was diminished in WT-Shc cells compared with
that in HIRc cells. Tyrosine phosphorylation of IRS-1 was also
decreased in 317Y/F-Shc cells and comparable to that in WT-Shc cells.
These results are summarized in Fig. 3B. Following 1 min of
insulin stimulation, tyrosine phosphorylation of IRS-1 was decreased to
46.9 ± 13.8% and 53.3 ± 5.5% by WT-Shc and 317Y/F-Shc
overexpression, respectively (results normalized to the amount of
tyrosine-phosphorylated insulin receptor
-subunit). Thus, both
overexpressed WT-Shc and 317Y/F-Shc appeared to be able to compete with
endogenous IRS-1 as substrates of the insulin receptor.
Effects of Antisense Shc mRNA on Tyrosine Phosphorylation of IRS-1
To further assess the competition between Shc and IRS-1 as
substrates of the insulin receptor, we transfected HIRc cells with RldnAS-Shc. Following selection, we isolated six individual clones. Of
these six, the clones demonstrating that Shc expression decreased to
50 ± 6% of that in the HIRc cells were chosen for further study (Fig. 4, A and C). HIRc and
antisense Shc cells were incubated with 17 nM insulin for
the indicated times, and the cell lysates were analyzed by
immunoblotting with anti-phosphotyrosine antibody. Reduction of Shc
expression by antisense Shc mRNA resulted in increased
insulin-stimulated tyrosine phosphorylation of IRS-1 compared with that
in HIRc cells (Fig. 4B), which is consistent with the
results showing that insulin-induced tyrosine phosphorylation of IRS-1
was decreased by overexpression of Shc as shown in Fig. 3. IRS-1
phosphorylation was increased to 186 ± 11% following 1 min of
insulin stimulation in antisense Shc cells compared with that in HIRc
cells as shown in Fig. 4D.
Effects of Shc Overexpression on Grb2 Association with Either Shc or IRS-1
Insulin stimulates the association of Shc with Grb2.
Phosphorylated Tyr-317 of Shc is reported to serve as a binding site for Grb2 (18, 20). Therefore, we assessed the effect of Shc overexpression on Shc association with Grb2 as shown in Fig.
5A. Grb2 was minimally associated with Shc in
the basal state in each cell line. Following insulin stimulation,
Shc·Grb2 association was increased in HIRc cells. Overexpression of
wild-type Shc resulted in an increased amount of Shc-associated Grb2
following insulin stimulation. In contrast, only a small amount of
insulin-stimulated Grb2 association with Shc was seen in 317Y/F-Shc
cells compared with that in HIRc cells. After 10 min of insulin
stimulation, Shc·Grb2 association was increased to 143 ± 24%
in WT-Shc cells and decreased to 46 ± 9% in 317Y/F-Shc cells
compared with that in HIRc cells as shown in Fig. 5B. To
examine the effect of Shc overexpression on IRS-1 association with
Grb2, the cell lysates were immunoprecipitated with anti-IRS-1
antibody, and the immunoprecipitates were analyzed by immunoblotting
with anti-Grb2 antibody. Compared with insulin-stimulated IRS-1
association with Grb2 in HIRc cells, the amount of IRS-1 association
with Grb2 was decreased in both wild-type Shc and 317Y/F-Shc cells
(Fig. 6A). Following 1 min of insulin
stimulation, IRS-1·Grb2 association was decreased to 56 ± 4%
and 58 ± 3% of control in WT-Shc and 317Y/F-Shc cells, respectively (Fig. 6B). These results suggest that
317Y/F-Shc can bind to the insulin receptor upon insulin stimulation,
but that it subsequently fails to be phosphorylated or bind to
Grb2.
Effects of Shc Overexpression on MAP Kinase Activation
The
activation of MAP kinase is important for insulin-induced DNA
synthesis. Phosphorylation of both tyrosine and threonine residues is
required for the activation of MAP kinase (29), and this
phosphorylation results in decreased mobility on SDS-PAGE (30).
Therefore, we next assessed insulin stimulation of MAP kinase activity
using the MAP kinase gel shift assay in transfected cell lines. As can
be seen in Fig. 7A, insulin treatment induced a time-dependent mobility shift of p42mapk (ERK-2)
in the transfected cell lines. These results are summarized in Fig.
7B. Insulin-stimulated MAP kinase activation was faster and
more prolonged in wild-type Shc-overexpressing cells. In contrast, the
MAP kinase gel shift was delayed, and only a transient activation was
seen in 317Y/F-Shc cells compared with that in HIRc cells.
Effects of Shc Overexpression on Insulin's Mitogenic Action
To study the mitogenic signaling properties of the
Shc-overexpressing cell lines, thymidine incorporation was assayed in
the transfected cell lines as shown in Fig. 8. Insulin
stimulated thymidine incorporation in a dose-dependent
manner with an ED50 value of 0.25 ± 0.07 nM in HIRc cells. Expression of WT-Shc led to enhanced
insulin sensitivity with a leftward shift of the dose-response curve
(ED50 value, 0.09 ± 0.04 nM). In
contrast, the insulin sensitivity was decreased with an
ED50 value of 0.49 ± 0.11 nM in
317Y/F-Shc cells. We also assessed insulin-induced mitogenesis by the
independent approach of BrdUrd incorporation. As shown in Fig.
9, the results of BrdUrd incorporation studies were
qualitatively similar to those of thymidine incorporation studies.
WT-Shc cells displayed enhanced sensitivity to insulin with an
ED50 value of 1.0 ± 0.3 nM compared with
2.8 ± 1.2 nM in HIRc cells, whereas the sensitivity was decreased with an ED50 value of 9.7 ± 1.8 nM in 317Y/F-Shc cells.
We showed that insulin-stimulated tyrosine phosphorylation of Shc and subsequent Shc association with Grb2 were increased by stable overexpression of wild-type Shc in Rat1 fibroblasts expressing insulin receptors. In addition, the time course of insulin-stimulated MAP kinase activation was more rapid, and more prolonged activation was observed in WT-Shc cells compared with that in parental HIRc cells. Furthermore, insulin sensitivity of both thymidine and BrdUrd incorporation studies was enhanced in wild-type Shc cells compared with that of the parental HIRc cells. Taken together with previous reports showing that Shc·Grb2·Sos, but not IRS-1·Grb2·Sos, is the predominant pathway coupling the activated insulin receptor to p21ras leading to DNA synthesis, and that microinjection of anti-Shc antibody inhibited insulin stimulation of DNA synthesis (12, 13), our results further support the important role of Shc in insulin-induced mitogenic signaling in Rat1 fibroblasts.
IRS-1 and Shc are the major intracellular substrates of the activated insulin receptor (2, 5). Since both IRS-1 and Shc interact with the juxtamembrane domain around Tyr-960 of the insulin receptor (15, 28), one can speculate that Shc and IRS-1 bind competitively to phosphorylated insulin receptors. Our results showed that stably overexpressed wild-type Shc could compete with endogenous IRS-1 for interaction with insulin receptors, since insulin-stimulated tyrosine phosphorylation of IRS-1 was decreased in WT-Shc cells compared with that in the parental HIRc cells, and reduction of Shc expression by antisense Shc mRNA enhanced insulin-stimulated tyrosine phosphorylation of IRS-1. These results clearly indicate that Shc and IRS-1 serve as competitive substrates of the insulin receptor. This idea was further supported by the fact that overexpression of wild-type Shc increased Shc·Grb2 association and decreased IRS-1·Grb2 association. Importantly, overexpression of the mutant 317Y/F-Shc also decreased insulin stimulation of IRS-1 phosphorylation as shown in Fig. 3. This result suggests that 317Y/F-Shc binds to the insulin receptor upon insulin stimulation, but that it subsequently fails to bind to Grb2. Therefore, overexpressed 317Y/F-Shc appears to function as a dominant-inhibitory mutant at the level of Grb2 association. The dominant-negative feature of exogenous 317Y/F-Shc overexpression was further supported by the fact that the time course of insulin-stimulated MAP kinase activation was delayed and transient in 317Y/F-Shc cells compared with that in the parental HIRc cells. Thus, the study of 317Y/F-Shc cells has important implications for further understanding the mechanisms of insulin's signal transduction through Shc Tyr-317 phosphorylation and its association with Grb2. Our results showed that overexpression of 317Y/F-Shc in Rat1 fibroblasts expressing insulin receptors led to decreased insulin sensitivity for stimulation of both thymidine and BrdUrd incorporation, causing a rightward shift of the insulin dose-response curve compared with that in HIRc cells as shown in Figs. 8 and 9. These findings demonstrate the essential role played by Shc Tyr-317 phosphorylation in insulin signaling to MAP kinase activation and mitogenic action in Rat1 fibroblasts. In this regard, Shc binding to other signaling molecules, which is not mediated by Shc Tyr-317 phosphorylation and subsequent association with Grb2, is not sufficient to transduce insulin's mitogenic signals.
It is somewhat surprising that insulin-induced thymidine and BrdUrd incorporation are only mildly impaired by overexpression of 317Y/F-Shc. There are several possible explanations for this finding. First, the expression level of the 317Y/F-Shc may not be sufficient to completely compete with endogenous Shc. Second, the 317Y/F-Shc may be phosphorylated on alternative tyrosines generating low affinity binding sites for Grb2, and this may prevent a major abnormality in the mitogenic effects of insulin. A previous study has indicated that Shc Tyr-240 is a candidate for an alternative tyrosine phosphorylation site (31). These possibilities are both consistent with our observation that insulin stimulation of Shc phosphorylation and subsequent association with Grb2 were not totally inhibited by 317Y/F-Shc overexpression. Third, one can speculate that other signaling pathways independent of Grb2 can partially compensate for the loss of the Shc·Grb2 pathway in p21ras activation. Along this line, it has been shown that SH-PTP2/Syp may activate p21ras through a non-Shc·Grb2 pathway. Overexpression of catalytically inactive SH-PTP2 inhibited insulin stimulation of p21ras activation without affecting tyrosine phosphorylation of Shc or Shc association with Grb2 (32-34). Furthermore, it is known that mammalian cells contain several p21ras guanine nucleotide exchange factors apart from Sos. C3G is one of these guanine nucleotide exchange factors that may activate p21ras (35). C3G, via its proline-rich region, binds to the amino-terminal domain of the adaptor protein Crk (35). The Crk·C3G pathway may compensate for diminished activity of the Shc·Grb2·Sos pathway in p21ras activation, although Rap1 rather than p21ras was recently identified as a preferred target for C3G in mammalian cells and the function of the Crk·C3G pathway in insulin signaling has not yet been characterized (36).
In summary, although Shc might associate with multiple downstream molecules through various sites, Shc Tyr-317 phosphorylation plays an essential role, via coupling with Grb2 and competition with IRS-1 as an insulin receptor substrate, in insulin-induced cell cycle progression.
We thank Dr. Hiroshi Maegawa (Shiga University of Medical Science, Japan) for the anti-IRS-1 antibody.